[{"address1": "12230 El Camino Real", "address2": "Suite 230", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 434 1113", "fax": "858 408 3010", "website": "https://www.oncternal.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.", "fullTimeEmployees": 27, "companyOfficers": [{"maxAge": 1, "name": "Dr. James B. Breitmeyer M.D., Ph.D.", "age": 69, "title": "President, CEO & Director", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 881355, "exercisedValue": 0, "unexercisedValue": 240953}, {"maxAge": 1, "name": "Mr. Richard G. Vincent CPA", "age": 59, "title": "CFO & Treasurer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 602843, "exercisedValue": 0, "unexercisedValue": 84897}, {"maxAge": 1, "name": "Dr. Rajesh  Krishnan Ph.D.", "age": 50, "title": "Chief Technical & Scientific Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chase C. Leavitt", "age": 41, "title": "General Counsel & Secretary", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Pablo  Urbaneja", "title": "Senior Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anita  Wiseth", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.24, "open": 1.21, "dayLow": 1.17, "dayHigh": 1.219, "regularMarketPreviousClose": 1.24, "regularMarketOpen": 1.21, "regularMarketDayLow": 1.17, "regularMarketDayHigh": 1.219, "beta": 1.358, "forwardPE": -0.11804879, "volume": 16605, "regularMarketVolume": 16605, "averageVolume": 40593, "averageVolume10days": 52790, "averageDailyVolume10Day": 52790, "marketCap": 3581164, "fiftyTwoWeekLow": 1.17, "fiftyTwoWeekHigh": 13.2, "priceToSalesTrailing12Months": 1.9399588, "fiftyDayAverage": 3.3452, "twoHundredDayAverage": 7.26025, "currency": "USD", "enterpriseValue": -17612830, "floatShares": 2706359, "sharesOutstanding": 2959640, "sharesShort": 24205, "sharesShortPriorMonth": 15389, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.0082, "heldPercentInsiders": 0.0923, "heldPercentInstitutions": 0.16332, "shortRatio": 0.41, "shortPercentOfFloat": 0.0085, "bookValue": 5.322, "priceToBook": 0.22735815, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -35973000, "trailingEps": -12.18, "forwardEps": -10.25, "lastSplitFactor": "1:7", "lastSplitDate": 1560124800, "enterpriseToRevenue": -9.541, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ONCT", "underlyingSymbol": "ONCT", "shortName": "Oncternal Therapeutics, Inc.", "longName": "Oncternal Therapeutics, Inc.", "firstTradeDateEpochUtc": 1075818600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fb3086bb-6779-3bd2-a1c4-93604c12e1a6", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.21, "targetHighPrice": 39.0, "targetLowPrice": 2.0, "targetMeanPrice": 20.5, "targetMedianPrice": 20.5, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 21429000, "totalCashPerShare": 7.24, "totalDebt": 235000, "quickRatio": 2.73, "currentRatio": 2.887, "totalRevenue": 1846000, "debtToEquity": 1.492, "revenuePerShare": 0.625, "returnOnAssets": -0.6309, "returnOnEquity": -1.18064, "freeCashflow": -10937500, "operatingCashflow": -25192000, "revenueGrowth": 6.557, "operatingMargins": -11.064919, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-10"}]